Opthea

29 articles with Opthea

• Opthea Announces Pricing of Initial Public Offering in the United States

  10/16/2020

  Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces the pricing of its initial public offering in the United States (the “Offering”) of 8,563,300 American Depositary Shares (“ADS”), representing 68,506,400 ordinary shares, at an initial public offering price of US$13.50 per ADS, before underwriting discounts

• Opthea Announces Launch of Proposed Initial Public Offering in the United States - Oct 12, 2020

  10/12/2020

  Opthea Limited, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, announces the launch of its initial public offering of American Depositary Shares, each of which will represent eight of the Company’s ordinary shares, in the United States.

• Opthea to Appoint Dr Jeremy Levin as Chairman of the Board

  10/5/2020

  Opthea Limited, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce that Jeremy Levin, DPhil, MB BChir will be appointed to the Company’s Board of Directors, effective October 12, 2020.

• Opthea Files Registration Statement for Proposed Initial Public Offering in the United States

  9/25/2020

  Opthea Limited announces the public filing of a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed public offering of American Depositary Shares, each of which will represent one or a number of the Company’s ordinary shares in the United States.

• Opthea Announces Plans to Conduct Registered Public Offering and Listing in the United States

  8/24/2020

  Opthea Limited announces that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential initial public offering of American Depositary Shares in the U.S. representing Opthea’s ordinary shares, which will remain listed on the Australian Securities Exchange, and concurrent listing of the ADSs on the Nasdaq Stock Market.

• Opthea Completes Successful Meetings with FDA and EMA for OPT-302 Phase 3 Clinical Program in Wet AMD

  8/21/2020

  Regulatory engagement provides clear pathway through Phase 3 to support filing for marketing approvals in US and Europe Regulatory agreement of using Lucentis ® and Eylea ® in combination with OPT-302 across two pivotal Phase 3 trials increases the potential multi-billion dollar market opportunity Lucentis ® and Eylea ® had combined sales for retinal diseases of USD11.9BN in 2019  Company on-track to initiate Phase 3 trials in early 2021        

• Opthea to Host Wet AMD and DME Key Opinion Leader Symposium on August 5, 2020 (EDT)

  7/28/2020

  Opthea Limited is pleased to announce that it will host a Key Opinion Leader symposium focused on OPT-302, the Company’s first-in-class biologic inhibitor of VEGF-C/D, in development for the treatment of wet age-related macular degeneration and diabetic macular edema.

• Opthea Reports New Data of OPT-302 in Diabetic Macular Edema at the 2020 Annual Meeting of the American Society of Retina SpecialistsCompany to host Key Opinion Leader Symposium on Wet AMD & DME on Aug 5th, 7:00pm EDT

  7/27/2020

  Opthea Limited, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce that new data from the Phase 1b/2a clinical study of OPT-302 in patients with treatment refractory diabetic macular edema has been presented at the 2020 American Society of Retina Specialists Virtual Annual Meeting.

• Opthea Clinical Data of OPT-302 in Diabetic Macular Edema to be Presented at American Society of Retina Specialists 2020 Annual Meeting

  7/23/2020

  Opthea Limited, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce that clinical trial results from the Phase 1b/2a study of OPT-302 in diabetic macular edema patients refractory to anti-VEGF-A therapy, will be presented at the upcoming American Society of Retina Specialists Annual 2020 Virtual Annual Meeting.

• Opthea Completes Patient Dosing in Phase 2a DME TrialCompany also provides business update in response to COVID-19

  3/30/2020

  Opthea Limited, a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed patient dosing and all follow-up week 12 patient visits in the Company’s Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept for treatment of diabetic macular edema.

• Opthea to Present at the 9th Annual SVB Leerink Global Healthcare Conference

  2/18/2020

  Opthea Limited announced that Dr Megan Baldwin, CEO of Opthea, will present and provide a corporate update at the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020 at 11am EST in New York City.

• Opthea Completes Recruitment in Phase 2a Clinical Trial of OPT-302 for Diabetic Macular Edema

  1/7/2020

  Opthea Limited, a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed patient recruitment into the Company’s Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept for treatment of diabetic macular edema.

• Opthea Presents Additional Data from OPT-302 Phase 2b Wet AMD Trial at the Ophthalmology Innovation Summit in San Francisco

  10/14/2019

  Opthea Limited announced that additional data analyses from the recently completed 366 patient Phase 2b randomised, controlled wet AMD study of OPT-302 with ranibizumab compared to ranibizumab alone, was presented at the Ophthalmology Innovation Summit in San Francisco.

• 

  Clinical Catch-Up: September 2-8

  9/9/2019

  Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.

• Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

  1/3/2018

  This marks the expansion of the clinical development program for OPT-302 into a second ocular indication and targets a severe complication of diabetes.

• Opthea Presents Additional Positive Data From OPT-302 Phase I/IIa Wet AMD Trial At ASRS Meeting

  8/16/2017

• Opthea To Present At The American Society Of Retinal Specialists Annual Meeting And The Ophthalmology Innovation Summit

  8/15/2017

• Opthea Receives Notice Of Allowance For Key Patent Covering OPT-302 In The United States

  7/6/2017

• Opthea Completes A $45 Million Capital Raising

  5/2/2017

• Opthea Reports Positive Phase I/IIA Clinical Results For OPT-302 In Wet AMD

  4/3/2017